The Impact of Comorbidities in Patients with Chronic Respiratory Diseases

Abebaw Mengistu Yohannes
DOI: https://doi.org/10.1007/978-1-4939-7009-4_9
2017-01-01
Abstract:Chronic respiratory diseases primarily affect the lung. Asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, lung cancer, lung fibrosis, sleep apnoea syndrome, pneumoconiosis and pleural diseases are common respiratory diseases worldwide. They present similar symptoms such as breathlessness on exertion, excess mucous production, chronic cough and wheezing. When these conditions are not adequately treated and/or become chronic may contribute to the development of systemic inflammatory comorbid disorders such as cardiovascular, musculoskeletal, psychiatric and cerebrovascular diseases. These comorbid disorders and pathophysiological mechanisms may vary in their manifestations, despite having similar symptoms. Comorbidities have major impact in patients with chronic respiratory diseases by impairing their quality of life, decreasing exercise capacity and increasing healthcare utilization. Therefore, it is important to screen patients with chronic respiratory diseases for comorbidities and monitor regularly. In addition, those identified with comorbidities should be referred for further assessment and to receive appropriate treatment which may include pharmacological therapy and non-pharmacological therapy (including exercise therapy and cognitive behavioural therapy) using a collaborative care model. Evidence from the available literature suggests that the effects of treating comorbidities in patients with chronic respiratory diseases are beneficial in short term improving quality-of-life patients and their caregivers. However, the long-term impact on clinical outcomes (e.g. healthcare utilization) is uncertain. Thus, well-controlled randomised control trails are needed.
What problem does this paper attempt to address?